- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01464242
Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis (GT)
Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Failure of first line therapies for cutaneous leishmaniasis is a public health issue. Since pathogenesis of dermal leishmaniasis is mediated by the immune and inflammatory responses, resolution of disease and control of infection are intimately linked to the host response. Several investigations have substantiated "proof of principal" for the therapeutic gain of co-adjuvant immunotherapy. This study will evaluate the efficacy and safety of using pentoxifylline (PTX) as a co-adjuvant in the treatment of cutaneous leishmaniasis with meglumine antimoniate in a randomized, double-blind, controlled trial. One arm will receive meglumine antimoniate and PTX and the other arm will receive meglumine antimoniate plus placebo. Efficacy will be assessed at the end of the treatment, and 5, 7, 13 and 26 weeks after initiation of treatment. Efficacy will be measured as the proportion of patients with definitive cure at 26 weeks after initiation of treatment, and time to healing. Safety will be assessed at the end of treatment with respect to the frequency and severity of adverse events.
Blood samples will be taken to evaluate the effects of PTX invitro and ex vivo on cells of the immune system. Proliferation and secretion of cytokines relevant to the immune and inflammatory responses by peripheral blood mononuclear cells will be measured before and after treatment. Likewise, macrophages will be differentiated from peripheral blood monocytes and infected with a strain of L. panamensis transfected with the luciferase (luc) gene. The investigators will measure the capacity of patient macrophages to kill parasites before and after treatment using a luminometric assay of viable parasite burden. Additionally, the investigators will measure the expression of inducible nitric oxide synthase, an enzyme that is necessary for nitric oxide production, one of the main leishmanicidal mechanisms used by macrophages. The investigators postulate that the use of the co-adjuvant with antimonials will increase the therapeutic response and that indicators predictive of a healing response can be identified by this prospective analysis of the immune response and therapeutic outcome.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Valle
-
Cali, Valle, Colombia, 5930
- Corporación Centro Internacional de entrenamiento e Investigaciónes Médicas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with clinical diagnosis of cutaneous leishmaniasis (parasitologic confirmation or presumptive biopsy plus a positive Montenegro skin test).
- Age between 18 and 65 years.
- Lesions of a duration equal to or greater than one month
- More than one lesion or single lesion greater than 3 cm in diameter.
- Willingness to participate in the study after being informed through a consent process approved by the institutional ethical review committee
Exclusion Criteria:
- Pregnant or lactating women, and women who are planning to conceive during the study or that reject the use of birth control methods.
- Medical conditions that compromise the immune system (HIV infection, neoplasias, diabetes mellitus, autoimmune diseases, or use of corticosteroids, immunomodulators or antineoplastic drugs).
- Medical conditions that preclude the use of antimonials or pentoxifylline (cardiac, renal, hepatic or pancreatic disease or abnormalities).
- Alcohol abuse or use of recreational drugs that interfere with adherence to treatment
- Use of drugs with antileishmanial potential during the previous 13 weeks, including pentavalent antimonials, amphotericin B, miltefosine, and pentamidine
- Use of Theophylline , anticoagulants or antiarrhythmics.
- Diffuse or disseminated leishmaniasis.
- Mucosal involvement secondary to Leishmania infection.
- Incapacity to attend the study visits or any other condition that according to the investigator could interfere with adherence to study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Glucantime® + pentoxifylline
Glucantime® 20mg/kg/day intramuscular injection (IM) daily for 20 days + pentoxifylline 400mg orally 3 times a day for 20 days.
|
Glucantime® 20mg/kg/day IM daily for 20 days
Other Names:
Pentoxifylline 400mg orally 3 times a day for 20 days
|
Placebo Comparator: Glucantime® + placebo
Glucantime® 20mg/kg/day IM each day for 20 days + placebo 400mg orally 3 times a day for 20 days.
|
Glucantime® 20mg/kg/day IM daily for 20 days
Other Names:
Placebo 400mg orally 3 times a day for 20 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary efficacy outcome: Definitive Cure
Time Frame: Participants will be followed up to 26 weeks
|
Definitive cure, defined as complete re-epithelialization and absence of inflammatory signs in all cutaneous leishmaniasis lesions, and absence of new leishmaniasis lesions
|
Participants will be followed up to 26 weeks
|
Primary safety outcome: Adverse Events
Time Frame: Participants will be followed up to 26 weeks
|
Clinical and laboratory adverse events will be qualified according to the Common Toxicity Criteria for Adverse Effects (CTCAE).
All unexpected non serious adverse events will be notified and expected adverse events of moderate or higher category will be reported.
All serious adverse events will be reported.
|
Participants will be followed up to 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In vitro lymphoproliferation
Time Frame: Participants will be followed for an average of 20 days
|
Proliferation of peripheral blood mononuclear cells (PBMCs) after stimulation invitro with L. panamensis antigens will be measured by tritiated thymidine uptake
|
Participants will be followed for an average of 20 days
|
Cytokine secretion by PBMCs
Time Frame: Participants will be followed for an average of 20 days
|
Secretion of a panel of cytokines relevant to the inflammatory and immune responses will be measured in supernatants from PBMCs cultured with L. panamensis antigens using Luminex technology
|
Participants will be followed for an average of 20 days
|
Macrophage leishmanicidal capacity
Time Frame: Participants will be followed for an average of 20 days
|
Macrophages will be differentiated from peripheral blood monocytes and their leishmanicidal capacity will be measured by luminometry after infecton with luciferase-transfected promastigotes.
|
Participants will be followed for an average of 20 days
|
Macrophage inducible nitric oxide synthase (iNOS) expression
Time Frame: Participants will be followed for an average of 20 days
|
Macrophage expression of iNOS after infection will be measured by quantitative real-time Polymerase Chain Reaction (RT-PCR).
|
Participants will be followed for an average of 20 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nancy C Saravia, PhD, Centro Internacional de Entrenamiento e Investigación Médica
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Skin Diseases, Parasitic
- Skin Diseases, Infectious
- Euglenozoa Infections
- Leishmaniasis
- Leishmaniasis, Cutaneous
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Anti-Infective Agents
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antioxidants
- Phosphodiesterase Inhibitors
- Free Radical Scavengers
- Radiation-Protective Agents
- Pentoxifylline
- Meglumine Antimoniate
Other Study ID Numbers
- 222951928964
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Leishmaniasis
-
Medecins Sans Frontieres, NetherlandsUnknownOld World Cutaneous Leishmaniasis
-
Drugs for Neglected DiseasesWellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable...CompletedVisceral Leishmaniasis | Cutaneous LeishmaniasesUnited Kingdom
-
Hospital Universitário Professor Edgard SantosOswaldo Cruz Foundation; Conselho Nacional de Desenvolvimento Científico e...CompletedCutaneous Leishmaniasis, AmericanBrazil
-
Fundacion Nacional de DermatologiaHospital Dermatologico de Jorochito; Ministerio de Salud de Bolivia, Programa... and other collaboratorsCompletedCutaneous Leishmaniasis, AmericanBolivia
-
Centro Internacional de Entrenamiento e Investigaciones...University of TexasCompletedCutaneous Leishmaniasis (Diagnosis)Colombia
-
Knight Therapeutics (USA) IncCompletedCutaneous Leishmaniasis | Mucosal LeishmaniasisUnited States
-
Hospital Universitário Professor Edgard SantosInstituto Gonçalo Muniz FIOCRUZ BANot yet recruitingCutaneous Leishmaniasis, AmericanBrazil
-
Centro Internacional de Entrenamiento e Investigaciones...Universidad IcesiCompletedCutaneous Leishmaniasis, AmericanColombia
-
University of BrasiliaCompletedLocalized Cutaneous LeishmaniasisBrazil
-
U.S. Army Medical Research and Development CommandCompletedOld World Cutaneous LeishmaniasisTunisia
Clinical Trials on Meglumine antimonate
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completed
-
Dongzhimen Hospital, BeijingCompletedStroke | Nervous System Diseases | Ischemic Stroke | Brain Ischemia | Cerebral Infarction | Brain InfarctionChina
-
Galmed Research and Development, Ltd.Virginia Commonwealth UniversityNot yet recruitingPrimary Sclerosing Cholangitis
-
PfizerCompletedTransthyretin Amyloid Polyneuropathy (ATTR-PN)China
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.CompletedIschemic StrokeChina
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completed
-
PfizerCompletedTransthyretin Familial Amyloid PolyneuropathyJapan
-
Lawson Health Research InstituteWithdrawnGastroschisis | Bowel Obstruction | Birth DefectCanada
-
Oswaldo Cruz FoundationConselho Nacional de Desenvolvimento Científico e Tecnológico; Rio de Janeiro...UnknownMucosal Leishmaniasis | Mucocutaneous LeishmaniasisBrazil
-
University of BrasiliaMinistry of Health, BrazilCompletedCutaneous LeishmaniasisBrazil